Ken Griffin
IDXG

Ken Griffin’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Ken Griffin’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-11,858
Closed -$37K – 11920
2020
Q3 		$37K Buy
+11,858
New +$53.7K ﹤0.01% 9704
2019
Q2 		– Sell
-3,262
Closed -$26K – 10239
2019
Q1 		$26K Buy
+3,262
New +$30.7K ﹤0.01% 9019
2018
Q3 		– Sell
-2,618
Closed -$23K – 9965
2018
Q2 		$23K Buy
+2,618
New +$23.2K ﹤0.01% 8617
2018
Q1 		– Sell
-1,928
Closed -$20K – 9057
2017
Q4 		$20K Buy
1,928
+43
+2% +$520 ﹤0.01% 7833
2017
Q3 		$29K Buy
+1,885
New +$22.3K ﹤0.01% 7295
2016
Q4 		– Sell
-1,086
Closed -$17K – 8144
2016
Q3 		$17K Buy
1,086
+603
+125% +$16.7K ﹤0.01% 7099
2016
Q2 		$16K Buy
+483
New +$18.2K ﹤0.01% 6681
2013
Q3 		– Sell
-144
Closed -$68K – 6951
2013
Q2 		$68K Buy
+144
New +$65.3K ﹤0.01% 5485

Other funds holding IDXG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Ken Griffin's IDXG Position: Q4 2020 in Review

Ken Griffin sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q4 2020, closing a stake of 11,858 shares — an estimated $37K sold.

Ken Griffin first reported a position in IDXG in Q2 2013 and held it in 8 quarters. The position peaked at $68K in Q2 2013. 12 funds tracked by Wall St. Rank hold IDXG as of Q4 2020.

  • Ken Griffin reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Ken Griffin sold 11,858 Interpace Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $37K.
  • Ken Griffin first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 8 quarters.
  • Ken Griffin's Interpace Biosciences, Inc. Common Stock position peaked at $68K in Q2 2013.
  • 12 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q4 2020.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.